Ayala Pharmaceuticals Inc (ADXS)

[Gantor50]

Something I find perplexing this year outside of ADXS is the relative lack of M&A activity in Biotech since Jan/Feb.

With clarity on the new tax plan resolved, and Billions available to be repatriated by Big Pharma, this was universally expected to be a year of huge M&A activity. So far it has not been.

So when talking about what ADXS can demand or expect for HER2, AXAL, HOT, etc...I am not sure why there is not more money flowing to Biotech than what we are seeing. It's not just ADXS that can't agree to terms with a Big Pharma suitor. The same story is being played out across the Biotech sector right now.

It's certainly not what I expected in 2018.